Bleakley Financial Group LLC Grows Stock Holdings in Kenvue Inc. $KVUE

Bleakley Financial Group LLC increased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 36.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 98,740 shares of the company’s stock after buying an additional 26,160 shares during the quarter. Bleakley Financial Group LLC’s holdings in Kenvue were worth $2,067,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Kenvue by 4.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock worth $2,545,000 after buying an additional 4,034 shares during the last quarter. Renaissance Capital LLC boosted its holdings in Kenvue by 8.3% in the 2nd quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock valued at $13,169,000 after purchasing an additional 48,267 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in Kenvue by 80.7% in the 2nd quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock valued at $758,000 after purchasing an additional 16,164 shares in the last quarter. Arlington Partners LLC purchased a new stake in Kenvue in the 2nd quarter valued at approximately $2,110,000. Finally, Cornell Pochily Investment Advisors Inc. boosted its holdings in Kenvue by 144.6% in the 2nd quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock valued at $694,000 after purchasing an additional 19,609 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

KVUE stock opened at $15.00 on Friday. The firm has a 50 day moving average of $17.91 and a 200-day moving average of $20.80. Kenvue Inc. has a 12-month low of $14.05 and a 12-month high of $25.17. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The company has a market cap of $28.78 billion, a price-to-earnings ratio of 20.26, a PEG ratio of 2.17 and a beta of 0.72.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. During the same period in the previous year, the firm posted $0.32 EPS. The company’s quarterly revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were given a dividend of $0.2075 per share. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 annualized dividend and a dividend yield of 5.5%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s payout ratio is presently 112.16%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. The Goldman Sachs Group lowered their price objective on Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a report on Thursday, October 2nd. Barclays lowered their price objective on Kenvue from $20.00 to $17.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 1st. JPMorgan Chase & Co. lowered their price objective on Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Deutsche Bank Aktiengesellschaft set a $18.00 price objective on Kenvue in a report on Friday. Finally, Rothschild Redb raised Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, September 26th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $20.75.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.